Galderma, the world-renowned Swiss leader in dermatology, opened its new headquarters for the United States and Latin America at the end of August in Miami's Brickell district. This strategic move taps into Miami's booming aesthetic medicine market, which serves as a gateway to the broader Latin American region.
With operations in nearly 90 countries, Galderma chose Miami for its affluent consumer base, the influx of medical tourists from Latin America, and its extensive network of specialized clinics.
Expanding Market in South Florida
The aesthetic medicine market in South Florida is projected to grow substantially, with estimates reaching $612 million by 2026 and potentially hitting $1.93 billion by 2035.
The new headquarters will gradually bring together around 200 employees, combining leadership teams from the U.S. and Latin America to streamline decision-making and commercial execution across both regions.
Advanced Training and Facilities
Located in Miami's financial district, the new facility is much more than just a corporate office. It features an injection room for hands-on training of healthcare professionals, educational programs, and a space inspired by the ALASTIN Signature Practice experience.
In 2026 alone, Galderma has organized over 1,000 training events for its network of aesthetic injectors in the U.S., involving approximately 5,000 participants.
Strategic Investments and Growth
CEO Flemming Ørnskov emphasized the strategic importance of this decision: "The United States is central to Galderma's long-term growth. This investment underscores our confidence in its continued expansion and our ambition to establish Galderma as a dermatology powerhouse, scientifically, commercially, and operationally."
The opening of the headquarters is part of a broader investment strategy, with Galderma committing over $650 million to U.S. manufacturing through 2030.
In the first half of 2026, the company reported global net sales of $3.134 billion, marking a 24.6% year-on-year increase at constant exchange rates, following record sales of $5.207 billion in 2025.
Market Presence and Regulatory Challenges
Just a month after the Miami inauguration, Galderma began trading on the Swiss Market Index, featuring among the top 20 Swiss stocks, with a market capitalization between 44.8 billion and 45.8 billion Swiss francs.
In 2023, the Florida Board of Medicine issued an emergency order to curb deaths linked to plastic surgery, with subsequent years seeing clinic suspensions and arrests for operating unlicensed post-surgery centers. Some plastic surgery centers in Miami have also been shut down for lacking required permits.
Galderma's portfolio includes brands like Dysport, Restylane, and Sculptra in injectable aesthetics; Cetaphil and Alastin in dermatological care; and Nemluvio in therapeutic dermatology.
Globally, the U.S. aesthetic medicine market is valued at $49.28 billion, with projected growth of nearly 13% annually through 2035, making Miami an appealing target for any industry heavyweight.
FAQs on Galderma's Expansion in Miami
Why did Galderma choose Miami for its new headquarters?
Galderma selected Miami due to its affluent consumer base, the influx of medical tourists from Latin America, and a dense network of specialized clinics.
What are the projected growth figures for the aesthetic medicine market in South Florida?
The market is expected to reach $612 million by 2026 and could potentially grow to $1.93 billion by 2035.
What recent initiatives has Galderma undertaken in the U.S.?
In 2026, Galderma organized over 1,000 training events for aesthetic injectors in the U.S., with around 5,000 participants involved.
How is Galderma addressing regulatory challenges in Florida?
Florida has seen emergency orders to reduce surgery-related deaths and clinic suspensions for licensing issues, which Galderma navigates by maintaining compliance with local regulations.